Eli Lilly (LLY)
(Delayed Data from NYSE)
$808.45 USD
+5.54 (0.69%)
Updated May 23, 2024 04:00 PM ET
After-Market: $808.20 -0.25 (-0.03%) 6:12 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 361 - 380 ( 428 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
CTADÂ’14: A Renewed Focus Toward the Development of Symptomatic Agents, and our Award for Preclinical ''''One to Watch''''
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
The Zyprexa Patent Expiration Has Largely Run Its Course
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S